Neurosearch A/s

Cadent Therapeutics, Inc.

Ataxion, Inc.

Aniona Aps

Dorte Strøbæk

Palle Christophersen

Ulrik Svane Sørensen

Dan Peters

Lene Teuber

Tina Holm Johansen

Birgitte Langer Eriksen

Karin Sandager Nielsen

Charlotte Hougaard

Joachim Demnitz

John Adams Lowe, Iii

John Michael McCall

Gregg F Keaney

Martin R Jefson

Janus Schreiber Larsen

Jeppe Kejser Christensen

Magnus Gustafsson

William Dalby Brown

Thomas Amos Jacobsen

Morten Grunnet

Søren Peter Olesen

Mads P G Korsgaard

Carsten Jessen

Rie S Hansen

Nadia Lybøl Von Schoubye

Jessica Klein

Antonio Nardi

David Spencer Jones

Elsebet ØStergaard Nielsen

Provided are novel compounds of Formula (I): and pharmaceutically acceptable salts thereof, which are useful for treating a variety of diseases, disorders or conditions which can be affected by potassium channel modulation. Also provided are pharmaceutical compositions comprising the novel compounds of Formula (I), pharmaceutically acceptable salts thereof, and methods for their use in treating one or more diseases, disorders or conditions, associated with potassium channels. 

Potassium channel modulators

This invention relates to novel substituted [1,2,4]triazolo[1,5-a]pyrimidines and their use as modulators of potassium channels. In other aspects the invention relates to the use of these compounds, in a method for therapy and to pharmaceutical compositions comprising the compounds of the invention.

Substituted [1,2,4]triazolo[1,5-a]pyrimidines and their use as potassium channel modulators

This invention provides 2,3-diamino-quinazolinone compounds of Formula (I) stereoisomers thereof, pharmaceutically-acceptable addition salts thereof, and N-oxides thereof, wherein the variables are as defined in the specification. The 2,3-diamino-quinazolinone compounds have medical utility. The 2,3-diamino-quinazolinone compounds can be used for the manufacture of medicaments, including pharmaceutical compositions. This invention also provides methods of treating disorders, diseases, or conditions which are responsive to activation of K7 channels.

2, 3-diamino-quinazolinone derivatives and their medical use

This invention relates to novel guanidine derivatives useful as modulators of small-conductance calcium-activated potassium channels (SK channels). In other aspects the invention relates to the use of these compounds in a method for therapy and to pharmaceutical compositions comprising the compounds of the invention.

Guanidine derivatives and their medical use

This invention relates to novel 2-amino-pyridine derivative useful as modulators of small-conductance calcium-activated potassium channels (SK channels). In other aspects the invention relates to the use of these compounds in a method for therapy and to pharmaceutical compositions comprising the compounds of the invention.

2-aminio-pyridine derivatives and their use as potassium channel modulators

This invention relates to novel 2-(phenylamino)benzimidazole derivatives useful as modulators of small-conductance calcium-activated potassium channels (SK channels). In other aspects the invention relates to the use of these compounds in a method for therapy and to pharmaceutical compositions comprising the compounds of the invention.

2-(phenylamino) benzimidazole derivatives and their use as modulators of small-conductance calcium-activated potassium channels

This invention relates to the use of ERG channel openers for the treatment of cardiac arrhythmias, and to the use of specific compounds for such treatment. In a separate aspect the invention provides novel compounds useful as ERG channel openers.

ERG channel openers for the treatment of cardiac arrhythmias

This invention relates to novel 2-amino benzimidazole derivatives useful as modulators of small-conductance calcium-activated potassium channels (SK channels). In other aspects the invention relates to the use of these compounds in a method for therapy and to pharmaceutical compositions comprising the compounds of the invention.

2-amino benzimidazole derivatives and their use as modulators of small-conductance calcium-activated potassium channels

Growing community of inventors

Farum, Denmark

Dorte Strøbæk